aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Peloton Therapeutics, founded in Dallas, is a clinical-stage pharmaceutical company dedicated to developing innovative cancer treatment drugs. The company's core mission is to translate novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. Peloton Therapeutics focuses on targeting HIF-2α, a transcription factor previously considered intractable using small molecules. Their pioneering work in HIF-2α biology has positioned them as leaders in this niche field.
Notable affiliated individuals include scientists and researchers who have significantly contributed to the understanding of HIF-2α biology. Peloton Therapeutics has attracted investments from prominent venture capital firms and strategic partners in the biotech industry. Key achievements include the development of the first HIF-2α inhibitor to enter clinical development, marking a significant milestone in cancer treatment research. The company's innovative approach has the potential to make a substantial impact on the lives of patients with cancer and other serious conditions.
Operating Status
Acquired
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Cancer Drugs
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Americas
When was Peloton Therapeutics founded?
Peloton Therapeutics was founded in 2010.
Where is Peloton Therapeutics's headquarters located?
Peloton Therapeutics's headquarters is located in DE, US.
When was Peloton Therapeutics's last funding round?
Peloton Therapeutics's most recent funding round was for $150M (USD) in February 2019.
How many employees does Peloton Therapeutics have?
Peloton Therapeutics has 75 employees as of Feb 5, 2024.
How much has Peloton Therapeutics raised to-date?
As of July 05, 2023, Peloton Therapeutics has raised a total of $242.6M (USD) since Feb 20, 2019.
Add Comparison
Total Raised to Date
$242.6M
USD
Last Update Feb 20, 2019
Last Deal Details
$150M
USD
Feb 20, 2019
Series E
Total Employees Over Time
75
As of Feb 2024
Peloton Therapeutics Address
Delaware
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts